"instanceType","uuid:ID","id","versionIdentifier","rationale"
"StudyVersion","542f3bae-ef2c-4cb6-895c-c37ed4da9481","StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
